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ABSTRACT  
Objective: The present research work was to formulate matrix tablets of diclofenac sodium using mucilage extracted from Tinospora cordifolia as a 
novel binding agent. Also, a comparative study on binding properties of mucilage and carbopol were performed. 
Methods: Fresh stems of Tinospora cordifolia were collected and mucilage was extracted out using standard method. The isolated mucilage was 
characterised for physicochemical parameters. Formulation of diclofenac sodium tablets (f1-f6) was done by dry granulation method using 2%, 4%, 
6%, 8% and 10% concentration of mucilage of Tinospora cardifolia as natural binder. Carbopol 2% was used as synthetic matrix forming agent. 
Microcrystalline cellulose was used as diluents, magnesium stearate and talc as lubricant. The formulated tablets were evaluated for parameters 
such as tablet thickness, hardness, weight variation, disintegration time, percent friability and in vitro drug release characteristics. The drug release 
mechanism was determined by fitting the release data into different kinetics models.  
Results: The results revealed that all the pre and post compression parameters of the formulated tablets (f1-f6) were in compliance with 
pharmacopoeial limits. In vitro drug release studies showed that formulation f6 containing maximum concentration of mucilage release the drug in 
a most controlled and sustained manner with maximum drug release of 63.6% in 15 h in comparison with f1(2% carbopol) giving 80% release and 
was found to be stable for 3 mo as indicated by stability studies. The mechanism of drug releases from formulation f1-f6 was found to be polymer 
disentanglement and erosion. Preformulation studies using FTIR study reveals that there is no incompatibility between the pure drug and mucilage 
of tinospora cardifolia used.  
Conclusion: Based on the experimental findings it can be concluded that Tinospora cordifolia mucilage can be used as a release retardant agent in 
the formulation of sustained release dosage forms. 
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In pharmaceutical dosage form various excipients and additives are 
mixed together to form a suitable dosage form for patient 
administration [1]. Each and every excipient has its own role to 
determine the quality and bioavailability of drug and binder is also 
one of the important excipient in tablet formulation [2]. Binders are 
the agents which hold various powders together to form a tablet. 
They impart cohesiveness to the granules to improve compression 
and flow properties which derived the hardness of tablet [3]. 
Different binders have different mechanical strengths and drug 
release properties to achieve different pharmaceutical purposes. 
While formulating the tablet, extensive knowledge of binder 
properties for enhancing the strength and also the interaction 
between various materials constituent should also be considered. 
This is the reason that development of new excipients as tablet 
binder is of continuous interest. Different types of polymers both 
natural and synthetic are used as binders in tablet formulation. 
Natural binders like starch, gums and mucilage are used widely due 
to their low cost, less toxicity, biocompatibility and environmental 
friendly processing[4, 5]. In the present work, an attempt has been 
made to formulate matrix tablets of diclofenac sodium an effective 
anti-inflammatory, analgesic and antipyretic drug. It has short 
biological half-life of 1.2-2h due which it is rapidly eliminated from 
the system so it would be a great advantage to formulate it as 
controlled released dosage form using mucilage extracted from fresh 
stems of Tinospora cordifolia (Menispermaceae). The objective of the 
work was to explore a novel natural binding agent and to formulate 
sustained released tablets of diclofenac sodium so as to reduce its 
frequent administration and to enhance patient compliance. Hence 
the novelty of the proposed work is the use of tinospora cardifolia 
mucilage as matrix forming agent to retard the release of drug. 
MATERIALS AND METHODS 
Materials 
Fresh stems of Tinospora cordifolia were collected locally from Rajpura, 
Punjab. Authentication of the sample was confirmed from Punjabi 
University Patiala, India and voucher specimen no is 03/2017/CCP 
(chitkara university, Punjab). Diclofenac sodium was obtained from 
Yarrow Chem Mumbai, India, carbopol from Ozone international 
Mumbai India, Magnesium stearate and talc used were of Loba Chem. 
Isolation of mucilage 
Fresh stems of Tinospora cordifolia was collected and thoroughly washed 
with water to remove impurities. The stem was sliced into half and then 
cut into small pieces. It was crushed and mixed with distilled water in a 
beaker and placed on the heating mantle at 100°C for four hours. The 
mass was kept soaking overnight. After 12 h the mass was filtered with 
muslin cloth and liquid was kept undisturbed. Carefully, the supernatant 
was decanted and collected in a separate beaker. Acetone was added 
slowly to the filtrate till precipitation is completed. The precipitate 
mucilage was separated and washed thrice with acetone to remove the 
traces of water. The separated mucilage was spread on a glass plate and 
dried at 45±0.5 °C. Dried mucilage was grinded and passed through sieve 
no. #60 and was stored in air tight container [6, 7].  
Physicochemical evaluation of mucilage 
The isolated mucilage was evaluated for various physicochemical 
properties [8]. 
Drug excipient compatibility studies 
Drug excipient compatibility studies were performed using Fourier 
transforms infra-red (FTIR) spectroscopy. FTIR spectra of the diclofenac 
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sodium, Tinospora cordifolia mucilage and combined mixture (1:1) of 
both were taken (Bruker Alpha T) within the range of 3500-500 cm-1
Formulation of diclofenac tablets was done by dry granulation 
method. Microcrystalline cellulose was used as diluents, 
magnesium stearate and talc as lubricant respectively. 2%, 4%, 
6%, 8% and 10% concentration of mucilage of Tinospora cardifolia 
was used as binder. All ingredients were weighed as per the 
composition given in the table 1 and passed through the sieve 
no.40 and mixed uniformly in geometrical order. The formulated 
blend was then subjected to compression to form slugs of 
hardness 4-4.5 kg/cm
  
Standard calibration curve of Diclofenac sodium  
To plot standard calibration curve of diclofenac sodium 100 mg of drug 
was weighed and transferred to 100 ml of volumetric flask and 10 ml of 
methanol was added to dissolve the drug and the volume was adjusted 
to 100 ml using 0.1 N HCL (stock I). 10 ml of solution was withdrawn 
from stock I to 100 ml volumetric flask and volume was made up to 100 
ml using 0.1 N HCL (stock II). Stock II was then used to prepare working 
standards by pipetting out 0.2, 0.4, 0.6, 0.8, 1and1.2 ml of solution in 10 
ml volumetric flask and finally the volume was adjusted to 10 ml. The 
absorbance of the resulting solution was measured at 276 nm using UV-
VS spectrophotometer [9]. 
Formulation of diclofenac sodium tablets 
2
Pre compression parameters  
. The slugs are then milled to granulate and 
screened through 22/44 mesh. Granules retained on sieve no. 44 
were lubricated and evaluated for various pre compression 
parameters. For comparison carbopol 2% was used as synthetic 
matrix forming agent. 
The formulation blends was characterized for pre compression 
parameters such as bulk density, tapped density, angle of repose and % 
compressibility to assess their flow behaviour and were compressed 
in to tablets using double punch tablet compression machine of 
weight equivalent to 200 mg [10]. 
 
Table 1: Composition of diclofenac sodium matrix tablets formulation (mg) 
Ingredients f1 f2 f3 f4 f5 f6 
Diclofenac 50 50 50 50 50 50 
Talc 5 5 5 5 5 5 
Magnesium Stearate 5 5 5 5 5 5 
Micro crystalline cellulose 132 132 128 124  120 116 
Carbopol 2% - - - - - 












(Quantities in mg/tablet) 
 
Characterization of tablets  
The prepared sustained released matrix tablets were evaluated for 
various post compression parameters like physical appearance, weight 
variation, hardness, friability, and disintegration time as per the official 
procedure. The hardness of the tablets was evaluated by Monsanto 
hardness tester. For hardness at random three tablets were taken 
from each formulation batch and average of three measurements was 
taken. For friability numbers of tablets equivalent to 6.5 gm were 
taken and placed in a friability chamber rotated at 25±1 rpm for 4 min 
and the percentage of weight loss was determined as an indicator of 
friability. The disintegration test was performed in phosphate buffer 
pH 6.8 at 37±0.5 °C. The disintegration time reported is an average of 
three determinations [11]. 
In vitro dissolution study  
The in vitro dissolution study of the various tablet formulations was 
performed using the USP dissolution test apparatus II paddle type 
(Electrolab, India). The dissolution study was done by placing one 
tablet in 900 ml of 0.1 N HCL (pH1.2) as dissolution medium 
maintained at 37±0.5 °C with a speed of 75 rpm.  
The amount of drug released was estimated by removing the 5 ml of 
dissolution medium at different time intervals, filtered (though 0.45 
μm), and absorbance was measured at 276 nm using Systronic 
double beam UV spectrophotometer [12]. 
Drug release kinetics  
To determine the order and mechanism of drug release from the 
formulated matrix tablets, the in vitro release data was fitted to 
kinetic models viz; zero order, first-order, Higuchi square root 
equation and Korsmeyer Peppas model. 
Q ¼ Q0+k0t (Zero order) 
In Q ¼= In Q0+k1t (First order) 
Q = KH tPn 
Q0
1/3 − QR
1/3= Kst (Hixson-Crowell) 
Q
QT�  = Kkp l
(Higuchi) 
n (Korsmeyer-peppas) 
Where Q is amount of drug release at time t, Q0 is the initial amount 
of drug, QR is the amount of drug remaining at time t, and QT is the 
total amount of drug release. k0, k1, kH, ks and Kkp
RESULTS AND DISCUSSION 
 are the kinetic 
constants for zero order, first order, Higuchi, Hixson-Crowell and 
Korsmeyer-Peppas models, respectively, and n is the release 
exponent [13-15]. 
Stability study  
The stability studies of selected tablet batches were carried out in 
stability chamber (Remi Instruments, India) kept at 40±0.5°C and 
75% RH conditions for three months. The effects of temperature 
and time on the physical characteristics and release profile of the 
tablet were evaluated to study the stability of the prepared 
formulations [16]. 
Physicochemical evaluation of mucilage 
The standard procedure was used to isolate mucilage from stems of 
Tinospora cordifolia. The total yield of mucilage by acetone 
precipitation method was found to be 15%. The isolated mucilage 
was of greyish white colour, odourless, mucilaginous taste and 
amorphous in nature. The isolated mucilage was evaluated for 
various physicochemical properties and results are listed in table 2. 
Standard calibration curve of Diclofenac sodium 
The standard calibration curve of diclofenac sodium was obtained by 
plotting absorbance versus concentration as shown in fig.1. The 
standard calibration curve shows the correlation coefficient of 0.990. 
Drug-excipients compatibility studies 
FTIR spectra of diclofenac sodium, Tinospora cordifolia mucilage and 
mixture of drug and mucilage are given in fig. 2, 3 and 4. Spectral 
analysis indicated all the important peaks of drug in the FTIR of drug 
and mucilage which means that diclofenac sodium is functionally 
compatible with the mucilage. 
Bala et al. 
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Table 2: Characterisation of Tinospora cordifolia mucilage 
S. No. Properties evaluated Observations 
1. Colour Greyish white 
2. Odour Odourless 
3. Taste Mucilaginous 
4. Solubility Forms colloidal solution in water and insoluble in ethanol and acetone 
5. % yield 15% 
6. Average particle size(µm) 161.18±0.23* 
7. Loss on drying 10% 
8. Swelling ratio(in distilled water) 8* 
9. pH (By digital pH meter) 6.2* 
10. Ash Value (%) 2.1±0.02* 
11. Viscosity (1% solution) 353 cps* 
12. Surface tension (0.1% w/v) 79.11±0.32 dynes/cm 
13. Test for Carbohydrates  
(Molisch’s test) 
+ve 
14. Test for reducing sugar 
(Fehling’s solution) 
+ve  
15. Test for Tannins (Ferric chloride test) -ve 
16. Test for Glycosides -ve 
17. Test for Starch -ve 
18. Test for Terpenoids -ve 
19.  Test for Flavonoids (shinoda test) +ve 
20. Test for saponins (foam test) -ve 
21. Test for alkaloids (Mayer’s test) -ve 
22. Test for Mucilage(Ruthenium red test) +ve 
23. Mucilage+Methylene blue Deep blue (+) 
24. Mucilage+Aqueous KOH Swell (+) 
25. Test for chlorides (silver nitrate test) -ve 
26. Test for Sulphates (barium chloride test) -ve 
27. Test for uronic acid +ve 
*Data are represented as mean±standard deviation (n=3), +ve = Positive,-ve = Negative 
 
 
Fig. 1: standard calibration curve of diclofenac sodium 
 
 
Fig. 2: FTIR of diclofenac 
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Fig. 3: FTIR of Tinospora cordifolia mucilage 
 
 
Fig. 4: FTIR of Tinospora cordifolia mucilage and diclofenac sodium 
 
Pre compression parameter 
Six different formulation batches of diclofenac sodium matrix 
tablets were prepared using different concentration of mucilage as 
a matrix forming agent to retard the drug release rate. The 
flowability of different formulation powder blend was assessed by 
using hausner ratio, Carr’s index and angle of repose. Hausner 
ratio values ranging between 1.25-1.42 appeared to indicate good 
flow characteristic. Carr’s index<16% of all formulations is 
indicative of good flow. In terms of angle of repose the value<25° 
ranging between 25.4-27.2 indicated average to good flowability. 
The results of pre compression characterisation of formulation 
blends (bulk density, tapped density, Carr’s index) are shown in 
table 3. 
 
Table 3: Characterisation of formulation blends of diclofenac matrix tablets 






Carr’ s Index a Hausnor ratio 
f1 0.572±0.01 0.789±0.02 25.6±0.21 12.4 1.25 
f2 0.514±0.11 0.763±0.03 27.2±0.11 12.8 1.38 
f3 0.557±0.02 0.767±0.11 26.8±0.05 13.2 1.42 
f4 0.571±0.10 0.754±0.01 27.5±0.23 12.7 1.26 
f5 0.563±0.01 0.761±0.02 25.4±0.01 13.8 1.30 
f6 0.523±0.02 0.80±0.11 26.2±0.02 13.4 1.28 
a
 
mean±SD, n = 3. 
Post compression parameter 
Microcrystalline cellulose was used in the formulation of sustained 
released matrix tablets of diclofenac sodium because of its versatility 
as direct compression excipient to improve the tablet ability of 
physical blend of the formulation. The average weight of all the 
formulations ranges between 199-206 mg which means all the 
formulations passed uniformity in weight test as per the 
pharmacopeia (±7.5% mean weight). All tablet formulations exhibit 
good mechanical strength with hardness ranging 4.3-6.0 kg/cm2. 
Formulation f6 containing 10% of mucilage exhibit maximum 
hardness of 6 kg/cm2. The friability test was carried out to measure 
the ability of tablets to withstand abrasion, chipping during 
handling, packaging and transportation and as per IP it should not 
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exceed 1%, all formulation showed percent friability in the range 
between 0.12-0.5% which means they passed the friability test as 
per the official specifications and has good mechanical resistance. 
Disintegration time increases as the concentration of mucilage 
increases, which may be due to strong binding potential of the 
increasing mucilage concentration and varies between 20-31 min, 
the results for characterisation are given in table 4 [17]. In vitro drug 
release decreases with increase in mucilage concentration. This may 
be due to the fact that at higher concentration of mucilage there is 
formation of dense matrix which reduces the mobility of drug 
particles and slow down the dissolution rate [18]. With f6 
formulation giving 63.6% release after 15 h and formulation f1 
containing 2% carbopol showed 80% release after 15 h. In vitro drug 
release profile of all the formulation batches is shown in fig. 5. 
 
Table 4: Characterisation diclofenac sodium matrix tablet formulations 
Formulation 
Code 






Disintegration time(min) Drug content (%)a a 
f1 201 4.3±0.27 3.7±0.15 0.5  20±0.01 98.2±0.05 
f2 200 4.5±0.11 3.2±0.02 0.21  22±0.33 99.4±0.12 
f3 205 4.6±0.23 4.3±0.21  0.3  24±0.24 97.5±0.11 
f4 199 5.0±0.15 4.7±0.02 0.2  25±0.06 99.3±0.25 
f5 200 5.3±0.22 4.0±0.05 0.3  30±0.32 99.2±0.01 
f6 206 6.0±0.23 3.7±0.21 0.12  31±0.24 98.7±0.21 
 a
 
mean±SD, n = 3. 
 
Fig. 5: In vitro drug release of dicofenace matrix tablet 
 
The release data as given in table 5 was fitted to various 
mathematical models to evaluate the kinetics and mechanism of 
drug release. The kinetic data of all formulations f-1 to f-6 could be 
best expressed by zero order equation as the plots showed highest 
linearity (R2
  
: 0.902 to 0.954). The n values obtained from Korsmeyer 
Peppas plots range from (0.804 to 1.122) indicate that mechanism of 
release from formulations f-1tof-6 was polymer disentanglement 
and erosion. 
Table 5: Release kinetic study diclofenac matrix tablets in 0.1N HCl at 37°C 
Formulations Zero order First order Higuchi Korsmeyer-Peppas 
(R2 (R) 2 (R) 2 (R) 2 Slope n ) 
f1 0.954 0.915 0.961 0.942 1.122 
f2 0.952 0.829 0.858 0.860 0.860 
f3 0.928 0.937 0.894 0.963 0.861 
f4 0.902 0.936 0.883 0.920 0.923 
f5 0.939 0.936 0.928 0.946 0.944 
f6 0.950 0.951 0.933 0.944 0.804 
 
Stability studies 
On the basis of in vitro drug released characteristics f-6 formulations was 
selected for stability studies. The test parameters were disintegration 
time, hardness, in vitro drug release and drug content. The results of 
stability study are shown in table 6, which indicates no remarkable 
change in the physical characteristics and release profile of the prepared 
formulation and was found to be stable for three months. 
 
Table 6: Stability studies of f6 formulation at 40 °C±2 °C/75% RH±5% 
Parameter  Days 
0 15 30 60 
In vitro drug release (%) 63.6 63.4 63 62.6 
Hardness (kg/cm2) 6.0±0.01 a 6.2±0.01 6.0±0.01 6.3±0.01 
Disintegration time (min) 31±0.01 a 32.3±0.11 31±0.25 30±0.06 
Drug content 98.7±0.21 a 97.2±0.03 98.2±0.11 98.3±0.22 
amean±SD, n = 3. 
Bala et al. 




The experimental data of the present research work carried out 
indicated the potential of Tinospora cardifolia mucilage as release 
retardant agent in the formulation of sustained release tablets of 
diclofenace. In vitro released studies of formulation f1-f6 showed, 
formulation f6 containing maximum amount of mucilage release the 
drug in a controlled and sustained manner with maximum amount of 
63.6% drug in 15 h. Hence it is concluded that Tinospora cardifolia 
can be utilized as natural matrix forming agent in the formulation of 
sustained released tablets. 
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